Amgen Inc. vs AT&T Inc.: Strategic Comparison

This in-depth comparison examines Amgen Inc. and AT&T Inc. across revenue, market value, business model, competitive positioning, and long-term growth strategy. Whether you are researching Amgen Inc. on its own, evaluating AT&T Inc., or weighing the two companies side by side, the breakdown below highlights where each company leads and where the gap between Amgen Inc. and AT&T Inc. is widest.

On the headline numbers, Amgen Inc. reports annual revenue of $36.8B against $125.6B for AT&T Inc., while their respective market capitalizations stand at $228.2B and $174.4B. Both Amgen Inc. and AT&T Inc. are headquartered in United States, so they compete in a shared home market and regulatory environment.

Amgen Inc.: Amgen is one of the companies that created the biotechnology industry. Instead of synthesizing small-molecule drugs, it engineers living cells to make complex proteins, an approach it first commercialized with Epogen in 1989. Based in Thousand Oaks, California, it is best known for medicines in bone health, inflammation, cardiovascular disease and kidney disease, and since the 2023 Horizon acquisition in rare disease. Fiscal 2025 revenue was US$36.8 billion across a portfolio in which 14 products each sold more than US$1 billion, although several of the older brands are now losing both price and volume.

AT&T Inc.: AT&T is one of the oldest names in telecommunications and now operates as a capital-heavy network business. It sold wireless service to 74.2 million postpaid phone subscribers at the end of 2025, sells fiber and fixed wireless broadband to households and businesses across the United States, runs business connectivity, and operates wireless networks in Mexico. After a decade-long detour into media through DirecTV and Time Warner, it separated WarnerMedia in 2022 and sold its remaining DIRECTV stake in July 2025, returning to building and running networks.

Amgen Inc. and AT&T Inc. pursue distinct approaches to generating revenue, and understanding how each company operates is the foundation of any fair comparison between Amgen Inc. and AT&T Inc..

Amgen Inc. business model: Amgen operates a high-risk, high-reward biopharmaceutical business model. It spends heavily on research to discover and engineer new biologic drugs: US$7.3 billion in fiscal 2025, or 20.7% of product sales. Once a drug is approved by the FDA, Amgen secures a patent, granting them a temporary monopoly to sell the drug at a premium price. Because biologic drugs are grown from living cells rather than chemically synthesized, they are much harder for competitors to copy, resulting in slightly longer and more defensible monopolies than traditional pills.

AT&T Inc. business model: AT&T runs a capital-intensive network business. It buys licensed wireless spectrum, builds and upgrades cell sites, and trenches fiber, then charges consumers and businesses a monthly fee to use that network. Capital investment was $22.0 billion in 2025 against $125.6 billion of revenue. Most of the revenue is recurring subscription revenue, so the economics turn on churn: postpaid phone churn was 0.98% in the fourth quarter of 2025. Device sales add about $22.1 billion a year at much lower margin than service.

The durability of a company's moat often decides long-term winners. Here is how the competitive advantages of Amgen Inc. stack up against those of AT&T Inc..

Amgen Inc. competitive advantage: Amgen's main competitive advantage is experience making complex biologics at commercial scale, which it has done continuously since Epogen launched in 1989. Producing a glycosylated protein or a monoclonal antibody to a consistent specification requires validated facilities, process know-how and a regulatory record that take years to build, which is also why the company can turn the same capability toward biosimilars of competitor products. Its balance sheet lets it buy late-stage assets rather than rely only on internal discovery: Onyx, Otezla, Five Prime, ChemoCentryx and Horizon together cost about US$57 billion between 2013 and 2023.

AT&T Inc. competitive advantage: AT&T's advantage is the cost of replicating what it already owns. Its fiber network passed 32.0 million consumer and business locations at the end of 2025, and its mid-band 5G service covers more than 310 million people. Keeping that going took $22.0 billion of capital investment in 2025 alone, which is why the national market has three carriers rather than thirty. AT&T also builds and operates FirstNet for the FirstNet Authority under a 25-year contract awarded in 2017, a public safety network with more than 7 million connections and no direct equivalent. Because connectivity is sold on monthly subscriptions, revenue moves slowly in both directions.

Future prospects matter as much as current results. The growth strategies below explain how Amgen Inc. and AT&T Inc. each plan to expand from here.

Amgen Inc. growth strategy: Amgen's growth plan has two parts: scale the newer medicines and buy what the pipeline does not supply. Recent launches and acquired products drove the 10% revenue growth in fiscal 2025, with Tezspire up 52% to US$1.48 billion, Repatha up 36% to US$3.02 billion, Evenity up 34% to US$2.10 billion, Uplizna up 73% to US$655 million and Imdelltra reaching US$627 million in its second year. The company is pushing into obesity with MariTide, now in six Phase 3 MARITIME studies, and runs a biosimilars business that produced about US$3.0 billion of fiscal 2025 sales across Pavblu, Mvasi, Amjevita and Wezlana.

AT&T Inc. growth strategy: With the US smartphone market saturated, AT&T's growth depends on home internet and on keeping the wireless customers it has. It is building fiber, which passed 32.0 million consumer and business locations at the end of 2025 and carried 10.4 million subscribers, and it sells AT&T Internet Air fixed wireless where fiber is not available. In wireless the emphasis is retention: AT&T offers existing customers the same trade-in promotions as switchers and spreads the credits over 36-month device installment plans, which held postpaid phone churn at 0.98% in the fourth quarter of 2025. The Lumen mass markets fiber purchase, completed in February 2026, added more than 1 million subscribers and more than 4 million fiber locations in metros including Denver, Seattle and Salt Lake City.

A closer look at the financial trajectory of Amgen Inc. and AT&T Inc. rounds out the comparison.

Amgen Inc.: Amgen is a cash-generative business with high product gross margins. In fiscal 2025 it reported US$36.8 billion of total revenues, US$7.7 billion of GAAP net income, a 25.8% GAAP operating margin, US$8.1 billion of free cash flow and US$5.1 billion of dividends paid. Its results used to depend on a few large franchises, first Epogen and Aranesp, then Enbrel. As those matured Amgen bought revenue instead: Onyx in 2013, Otezla in 2019 and Horizon Therapeutics for US$27.8 billion in 2023. That last deal is also the main reason for the balance sheet it now carries, with US$54.6 billion of debt outstanding at December 31, 2025, debt leverage of about 3.2 times EBITDA and US$2.8 billion of net interest expense in fiscal 2025.

AT&T Inc.: AT&T's financial story is large revenue, large debt and a slow correction. The company funded the $48.5 billion DirecTV purchase in 2015 and the $85.4 billion Time Warner purchase in 2018 largely with borrowing, and net debt passed $180 billion after Time Warner closed. It then reversed course: WarnerMedia was separated in 2022, the dividend was cut, and the remaining 70% DIRECTV stake went to TPG in July 2025 for a $5.6 billion gain. FY2025 revenue was $125.6 billion, with $23.4 billion of total net income, $46.4 billion of adjusted EBITDA and $16.6 billion of free cash flow against $117.4 billion of net debt. Roughly $22 billion a year of capital investment goes mostly into fiber and 5G.